{"id":"lutetium-177lu-oxodotreotide-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Hematologic toxicity (anemia, thrombocytopenia, leukopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Renal toxicity"},{"rate":null,"effect":"Hepatic toxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This radiopharmaceutical combines lutetium-177, a beta-emitting radionuclide, with oxodotreotide, a somatostatin receptor 2 (SSTR2)-targeting peptide. The peptide binds with high affinity to somatostatin receptors overexpressed on neuroendocrine tumor cells, allowing the radioactive lutetium-177 to deliver localized cytotoxic radiation directly to tumor tissue while minimizing exposure to healthy cells.","oneSentence":"Lutetium-177 oxodotreotide is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation therapy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:50.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuroendocrine tumors (NET) expressing somatostatin receptors"},{"name":"Gastroenteropancreatic neuroendocrine tumors (GEP-NET)"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["177Lu-DOTA0-Tyr3-Octreotate"],"phase":"phase_3","status":"active","brandName":"Lutetium[177Lu] Oxodotreotide Injection","genericName":"Lutetium[177Lu] Oxodotreotide Injection","companyName":"Sinotau Pharmaceutical Group","companyId":"sinotau-pharmaceutical-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lutetium-177 oxodotreotide is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation therapy. Used for Neuroendocrine tumors (NET) expressing somatostatin receptors, Gastroenteropancreatic neuroendocrine tumors (GEP-NET).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}